Sinovac Biotech Ltd, a biopharmaceutical product provider in China, announced on Tuesday that a phase-3 clinical trial for its inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile.
The clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3-year-old and above.
In total, 1,600 volunteers will be recruited. Half of them will receive one or two doses of the Sinovac vaccine, while the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
All of the participants will be observed for 28 days following the completed inoculation to evaluate the vaccine safety.
The study results are expected to provide further scientific evidence on the efficacy and safety of the company"s quadrivalent influenza vaccine to promote its worldwide use, Sinovac said.
The quadrivalent influenza vaccine has been approved in China since June 2020.
